News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article examines three dividend stocks—Abbott Laboratories (ABT), Consolidated Water (
AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …
For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …
AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …
AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …
On Thursday, Abbott Laboratories (ABT) shares fell by 2.21% to $105.61, despite a strong trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. This decline ended a six-day winning streak for the stock.
AbbVie Inc. (ABBV) shares declined by 2.24% to $257.41, breaking a two-day winning streak, despite an overall positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on Thursday. This report highlights AbbVie's performance …
What To Expect From AbbVie's (ABBV) Q2 Earnings Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here's what to look for. AbbVie beat analysts' revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Abbott Laboratories reported mixed Q2 2026 results with increased sales but lower net income and diluted EPS. Despite this, the company's stock rose 7.4% due to strengthening its medical device and diagnostics portfolio, including a significant real-world TriClip heart valve study and expansion in …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …
Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%This article provides a revenue breakdown for AbbVie, Inc. CDR (CAD Hedged) under the ticker NEO:ABBV, sourced from TradingView. It highlights that the United States was the primary contributor to AbbVie's revenue, bringing in 65.12 billion CAD last year and 58.95 billion CAD the …
This article provides a revenue breakdown for AbbVie, Inc. Brazilian Depository Receipts (ABBV34) traded on the BMFBOVESPA, highlighting that the United States is the largest contributor to its revenue. The financial data indicates significant revenue in BRL during the last two years.
AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven …
Sharemaestro market context Trend signal active 52 weeks +9.6%AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, is usually considered a blue chip dividend stock rather than a higher-growth one. Yet over the past five years, its stock has rallied 125% and delivered a total return of 170% with reinvested dividends. …
This article details the shareholder structure of Abbott Laboratories (ABT), listing its major shareholders and institutional holdings. It provides a breakdown of the largest individual shareholders like Vanguard and BlackRock, as well as categorizes shareholder types such as investment advisors and pension funds. The …
AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. This approval marks Rinvoq as the first systemic treatment of its kind for …
Sharemaestro market context Trend signal active 52 weeks +9.6%RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%The European Commission has approved AbbVie's RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 and older. This approval is supported by Phase 3 trials where RINVOQ demonstrated significant scalp hair regrowth, including complete regrowth in some patients, at both …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …
UBS has revised its price target for Abbott Laboratories (ABT) to $125, down from the previous $135, while reiterating a Buy rating on the stock. This adjustment reflects a moderated outlook but continues to signal confidence in the company's performance. The stock's current performance …
The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.
AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Search by ticker symbol or company name and select a result to open its chart.